SAN FRANCISCO – Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.  

Experts in genitourinary cancers are available to comment on the studies below and ASCO’s Media Team can assist you in arranging interviews with study authors and/or outside experts.  
 

Thursday Presentations 
The embargo on the following abstracts will lift at 5:00 PM (ET) on Monday, February 13, 2023: 

Abstract 18: Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
View the full abstract (Abstract presentation part of session beginning at 7:45 AM (PT) on Thursday, February 16)
“Rucaparib is superior to all existing standard therapies for patients with BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with at least one modern Androgen Pathway Inhibitor and is the first drug to ever beat a docetaxel containing control arm for mCRPC. In the long term, this study validates rucaparib as a superior treatment option for patients with BRCA-mutated mCRPC,” said lead study author Alan Haruo Bryce, MD.

Abstract 15: Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.
View the full abstract (Abstract presentation part of session beginning at 10:00 AM (PT) on Thursday, February 16)

Abstract 176: First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
View the full abstract (Abstract presentation part of poster session beginning at 11:30 AM (PT) on Thursday, February 16)
“If the encouraging efficacy and safety results from this Phase 2a study are validated with additional clinical studies underway, the combination of BXCL701 and pembrolizumab may eventually become a new treatment option for this high risk form of prostate cancer with an unmet need for new treatments following platinum-based chemotherapy,” said lead study author Rahul Raj Aggarwal, MD.

Abstract 170: Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.
View the full abstract (Abstract presentation part of poster session beginning at 11:30 AM (PT) on Thursday, February 16)

Abstract 20: Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
View the full abstract (Abstract presentation part of session beginning at 4:45 PM (PT) on Thursday, February 16)

Friday Presentations
The embargo on the following abstracts will lift at 10:00 AM (ET) on Friday, February 17, 2023: 

Abstract LBA442: Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
View the full abstract (Abstract presentation part of session beginning at 2:00 PM (PT) on Friday, February 17)
“Results suggest that patients with papillary high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG) who declined or were ineligible for radical cystectomy may benefit from pembrolizumab monotherapy, extending previous findings related to the population of patients with carcinoma in situ component, with or without a papillary tumor. These results are among the most robust data (in terms of sample size and follow-up duration) for a novel systemic therapy used to treat BCG unresponsive papillary HR NMIBC,” said lead study author Andrea Necchi, MD.

Abstract LBA443: Extended follow-up results from the CheckMate 274 trial.
View the full abstract (Abstract presentation part of session beginning at 2:00 PM (PT) on Friday, February 17)
“Now, with minimum follow-up of 31.6 months in the intent-to-treat population, median disease-free survival with nivolumab was doubled compared with placebo. In the PD-L1 ≥ 1% population, median disease-free survival with nivolumab was more than six times the median disease-free survival with the placebo arm. These results reinforce adjuvant nivolumab as a standard of care for patients with muscle-invasive urothelial cancer at high risk for recurrence after radical surgery,” said lead study author Matt D. Galsky, MD, FASCO.

Saturday Presentations 
The embargo on the following abstracts will lift at 5:00 PM (ET) on Monday, February 13, 2023: 

Abstract 607: Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
View the full abstract (Abstract presentation part of session beginning at 7:00 AM (PT) on Saturday, February 18)
“With a median follow-up of 46 months, this is the first report of overall survival data as well as efficacy results of second-line treatment, and we confirm the high efficacy of nivolumab-ipilimumab in patients with ccrcc4 tumours, the sensitivity of ccrcc2 tumours to VEGFR-TKI alone and the overall superior efficacy of nivolumab-ipilimumab over nivolumab alone. Our results suggest that efficacy of TKI in second-line treatment may be influenced by molecular group (higher efficacy in ccrcc2) and by the treatment received in first-line treatment (higher efficacy after nivolumab-ipilimumab vs nivolumab alone in ccrcc4). These results help us to generate new hypotheses and support the concept of biomarker-based clinical trials,” said lead study author Yann-Alexandre Vano, MD, PhD.
 

View the disclosures for the 2023 ASCO Genitourinary Cancers Symposium News Planning Team: https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2022-08/GU23-%20Committee%20Disclosure%20Report%20%281%29.pdf?mrQMAmMUytE1drtRz3uenQQS_P93k61y ​

ATTRIBUTION TO THE 2023 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE. 

###